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One sentence summary: 
Conserved noncoding sequences exhibiting human-specific accelerated evolution are identified 
and shown to be enriched near genes involved in neuronal cell adhesion, suggesting a cis-
regulatory contribution to the rise of human-specific cognitive traits. 
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Online Abstract 
Changes in gene regulation likely influenced the profound phenotypic divergence of humans 
from other mammals, but the extent of adaptive substitution in human regulatory sequences 
remains unknown. We identified 1,119 conserved noncoding sequences (CNSs) with a 
significant excess of human-specific substitutions.  These accelerated elements were 
disproportionately found near genes involved in neuronal cell adhesion. To assess the uniqueness 
of human noncoding evolution, we examined CNSs accelerated in chimpanzee and mouse. 
Although we observed a similar general trend towards neuronal adhesion in chimpanzee, the 
accelerated CNSs themselves exhibited almost no overlap with human, raising the possibility of 
independent evolution towards different neuronal phenotypes in each species. CNSs accelerated 
in mouse showed no bias toward neuronal cell adhesion. Our results indicate that widespread cis-
regulatory changes in human evolution may have contributed to uniquely human features of 
brain development and function. 
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The distinctively human traits that distinguish us from all other primates originated in 
human-specific DNA sequence changes. To investigate whether gene regulatory or other 
functional noncoding elements in the human genome bear the signature of accelerated evolution, 
we determined the occurrence of human-specific substitutions in 129,405 conserved noncoding 
sequences (CNSs) previously identified by multiple whole-genome sequence comparisons (1).  
We developed a test statistic that evaluated the likelihood of observing the configuration 
of human-specific substitutions present in a given CNS. We assigned each CNS a human-
acceleration P-value based on the probability of observing a configuration of equal or smaller 
likelihood under the null model of constrained evolution (1). We identified 1,119 elements 
(0.86%) with a significant excess of human-specific substitutions at P < 0.005, 73% more than 
we would expect to see by chance at this P-value threshold (Figure 1A).   
To ascertain in an unbiased manner if accelerated CNSs disproportionately occur near 
genes with particular functions, we determined the closest neighboring RefSeq gene for all 
129,405 CNSs, obtained the Gene Ontology (GO) annotations for each gene, and assigned those 
annotations to each CNS. We then sought to identify GO terms with a significant excess of 
accelerated CNSs. P-value thresholds were set to adjust for multiple testing (1). 
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Figure 1. (A) Observed distribution of human-acceleration P-values in 129,405 CNSs versus the 
uniform distribution expected by random chance. (B) GO biological process and cellular 
component terms significantly enriched in accelerated CNSs. (C) Human-accelerated CNSs are 
disproportionately associated with genes functioning specifically in neuronal cell adhesion.  
There is a highly significant excess of accelerated CNSs that occur near genes with both GO cell 
adhesion and Entrez Gene neuronal annotations (left). However, the number of accelerated CNSs 
near genes with only Entrez Gene neuronal (center) or only GO cell adhesion annotation (right) 
is not significantly greater than expected by chance. 
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The GO cellular component term most significantly enriched in accelerated CNSs was 
basal lamina (Figure 1B).  Of the 13 accelerated CNSs in this category, 10 were associated with 
the dystrophin-associated glycoprotein complex, disruptions of which cause muscle and neuronal 
diseases (2, 3). Cell adhesion was the only biological process displaying a significant excess of 
CNSs accelerated in human (Figure 1B). Many of the cell-adhesion accelerated CNSs were 
associated with genes involved in neuronal cell adhesion, such as cadherins and protocadherins, 
contactins, neuroligins, and classical neuronal cell adhesion molecules.  To quantitatively 
evaluate this observation, we constructed a composite neuronal adhesion GO term by 
intersecting GO “cell adhesion” genes with genes annotated in the Entrez Gene database as 
having evidence of neuronal function. We found a highly significant excess of accelerated CNSs 
neighboring genes with both GO cell adhesion and Entrez Gene neuronal annotations (P = 
0.00092, Fisher’s exact test, one-sided; Figure 1C; Table S1D).  However, when these 
overlapping accelerated CNSs were removed from the analysis, the number of accelerated CNSs 
with only GO cell adhesion or Entrez Gene neuronal function annotations was not significantly 
greater than expected. Thus, the strongest signal of human-specific noncoding sequence 
evolution we detected was an excess of accelerated CNSs near genes specifically involved in 
neuronal cell adhesion, rather than the more general categories of cell adhesion or neuronal 
function.  
To determine if the pattern of noncoding sequence acceleration we observed in the 
human lineage was recapitulated in other lineages, we identified accelerated CNSs in 
chimpanzee and mouse (1).  We observe 1,180 accelerated CNSs in chimpanzee, only 38 (3.2%) 
of which were also accelerated in human, indicating a general lack of overlap between human 
and chimpanzee accelerated CNSs (Table S1, A and B).  While accelerated CNSs in chimpanzee 
showed little overlap with human, they were also significantly enriched near neuronal cell 
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adhesion genes (expected = 54, observed = 77, P = 0.0017; Table S1E).  These results suggest 
independent accelerated evolution of neuronal cell adhesion functions in both the human and 
chimpanzee lineages. To determine if this was a general phenomenon among mammals, we 
examined the 5,058 CNSs accelerated in mouse and failed to detect any enrichment near genes 
involved in neuronal cell adhesion (expected = 234, observed = 207, P = 0.97; Table S1, C and 
F). 
Our results suggest that the disproportionate association of accelerated CNSs with 
neuronal cell adhesion genes in human and chimpanzee reflects evolutionary processes specific 
to those lineages, rather than a general property of noncoding sequence acceleration in mammals. 
This observation is consistent with the rapid evolution of behavioral and cognitive traits seen in 
both humans and chimpanzees (4).  Since the CNSs accelerated in the two lineages are largely 
disjoint, it is unlikely that the acceleration of neuronal adhesion CNSs in humans and 
chimpanzees results in the same neuronal phenotypes in the two species.  These findings suggest 
that cis-regulatory and other noncoding changes may have contributed to the modifications in 
brain development and function that gave rise to uniquely human cognitive traits.  
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Supplemental online material 
 
Materials and Methods 
Identification of human-accelerated CNSs 
CNS Filtering 
We obtained whole-genome alignments as well as a genome-wide set of 186,675 human 
conserved regions identified in multiz 8-way genomic alignments by the phastCons program (1) 
as having a conservation score >= 400 from the UCSC Genome Browser 
(www.genome.ucsc.edu). These conserved regions were filtered for overlap with human 
mRNAs, human spliced ESTs, nonhuman mRNAs, retroposed genes or duplicated blocks 
annotated in the browser's self-chain track. 
 
Neutral rate estimation 
To quantify background noncoding (approximately neutral) evolutionary rates, which exhibit 
lineage- and locus-specific variation, we segmented the human genome into non-overlapping 1-
Mb windows, appended marginal fragments shorter than 500 kb to the preceding window, 
excised all annotated known genes, retroposed genes, duplicated blocks and phastCons 
conserved regions (score >= 300), discarded windows aligned to < 50 kb in chimpanzee, mouse, 
rat or dog (insufficient data), and estimated substitution rates along each mammalian lineage in 
each window using fastDNAml (2). CNSs within retained windows were assigned background 
evolutionary rates and GC content by cubic-spline interpolation between window centers.  CNSs 
with < 50 bp aligned in any of the five mammals were eliminated, and within-CNS substitution 
rates were estimated for the rest, assuming asymptoticity of the local background GC content. 
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Identification of human-specific substitutions 
To identify CNSs within this set that contained an excess of human-specific substitutions, we 
empirically constructed a null model of human-lineage substitution probabilities in CNSs that 
accounted for four major sources of heterogeneity in CNS evolution: 1) variation in degree of 
constraint from position to position within a CNS, 2) variation in average constraint among 
CNSs, 3) lineage-specific variation in the local neutral rate of evolution (3) and 4) genome-wide 
relaxation of constraint in primates (4). 
 
To account for rate variation among sites within a single CNS, we binned sites by their depth of 
conservation. We considered sites conserved in chimpanzee, rhesus macaque, mouse, rat, dog 
and chicken (Type 1, most constrained), sites conserved in chimpanzee, rhesus, mouse, rat and 
dog but substituted or absent in chicken (Type 2), and sites conserved only between chimpanzee 
and rhesus macaque (Type 3, least constrained). Rhesus orthologs were grafted from the multiz 
17-way genome alignments into the 8-way alignments. We identified human-specific 
substitutions at Type1, Type 2 and Type 3 sites by parsimony as well as all Type 1, Type 2 and 
Type3 sites where human was identical to the other lineages.  We filtered all sites for low 
sequence quality chimpanzee, rhesus, dog and chicken positions (Phred Q < 30) and for 
annotated human SNPs.  We then generated counts of human-specific substitutions (K) and 
unsubstituted sites (N) of each type for each CNS. 
 
Binning of CNSs by non-human constraint 
To quantify evolutionary constraint in terms of sequence conservation, we defined the 
“constraint factor” C of a CNS or class of sites as the average ratio of its substitution rate to the 
local neutral rate. Thus, C = 0 implies extreme constraint, whereas C = 1 signifies neutral 
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evolution. Since C varies among lineages, and also among CNSs, we binned CNSs by their non-
human constraint factor CNON, which was determined from summed CNS and background rates 
over the chimpanzee, mouse, rat and dog lineages. We set an arbitrary threshold of CNON <= 0.4 
to eliminate phastCons predictions resulting from spurious alignments to low-complexity regions 
or human contamination in distant vertebrates, which yielded 129,405 CNSs for analysis of 
human-lineage acceleration. 
 
Estimating human-specific substitution rate at each site type  
The average human-lineage constraint factor CT,nHUM at all sites in the genome within each two-
dimensional category (defined by site type T and non-human constraint factor bin n) was 
estimated by maximum likelihood from counts of human-substituted KT,n( i )  and conserved 
NT,n( i ) sites in all CNSs i within the same bin n, and their associated human-lineage background 
neutral rates RBGHUM (i) as: CT,nHUM ≈ ∑ i KT,n( i ) /∑ i [RBGHUM (i) NT,n( i )]. Thus, the estimated 
human-specific substitution rate at a site of type T in CNS i, which lies in constraint-factor bin n 
is: RT,nHUM (i)= RBGHUM (i)CT,nHUM. To our knowledge, this is the first model of CNS evolution that 
accounts for variation of constraint among lineages and among sites within a CNS, as well as 
lineage- and locus-specific neutral rate variation. 
 
Calculating acceleration P-values 
The probability of specific human-lineage substitutions (for example, A->C) was calculated from 
the human-specific substitution rate RT,nHUM (i) based on the HKY substitution model (5) 
parameterized by the local human GC-content and transition-transversion bias = 4.2, estimated 
from concatenated whole-genome CNSs using PAML (6). The negative log-probability of the 
observed human-specific substitution or conservation event at an individual site k is defined as 
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the site-specific human-lineage surprisal sHUM(k). If we assume that each CNS site evolves 
independently in the human lineage, the aggregate surprisal SHUM = ∑k sHUM(k) of a CNS 
constitutes an information-theoretic statistic summarizing the “surprisingness” of the observed 
configuration of human-lineage substitutions under the null model of sequence constraint, given 
the number of strong (G,C) and weak (A,T) Type 1, 2 and 3 positions within the CNS, the non-
human constraint factor, the local human neutral rate and the local human GC-content. We 
calculated the CNS-specific probability distribution of SHUM for each CNS under the null model 
of human evolution by convolving the distributions of the site-specific surprisals sHUM(k). The P-
value of human-specific acceleration within a CNS is the probability of observing a surprisal 
greater than or equal to the actual value. By the definition of P-values, the expected number of 
CNSs in any P-value bin of width w is w*129,405 under the null model of constrained human-
lineage evolution (w = 0.00125 in Figure 1). Thus, we expect only 647 human-accelerated CNSs 
at a P-value threshold of 0.005 (0.5%), though we observe 1,119 (0.86%). 
 
Quantifying CpG effects 
Since our null model of constrained noncoding evolution does not account for the high 
mutability of CpG dinucleotides, we performed a worst-case simulation of CpG noise by 
randomly introducing CpG to TpG transitions into human CNSs at a rate of 0.06 substitutions 
per CpG dinucleotide. This corresponds to the assumption that CpG to TpG transitions in CNSs 
occur at ~8 times the non-CpG rate (7), and that all such transitions in the human or chimpanzee 
lineage will be counted as human-specific substitutions. In reality, many of the chimpanzee-
specific substitutions will be correctly identified as belonging to the chimpanzee lineage. We saw 
very little change in the number of accelerated CNSs detected, indicating that CpG effects are an 
unlikely explanation for the 472 extra accelerated elements we observe in the genome. This is 
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probably due to the fact that only ~1% of the dinucleotides in our CNS set are CpG. 
 
Parallel studies in chimpanzee and mouse 
Chimpanzee-specific CNS acceleration was identified exactly as described above, based on 
chimpanzee-specific Type 1, 2 and 3 substitutions. Since the aligned species set contains only 
two rodents (mouse and rat), the Type 3 parsimony category has no rodent equivalent. We 
therefore analyzed mouse-lineage CNS acceleration solely on the basis of Type 1 (conserved in 
human, chimpanzee, rat, dog and chicken) and Type 2 (conserved only in human, chimpanzee, 
rat and dog) positions.  We verified that the human and chimpanzee GO term results described in 
the manuscript are robust even when Type 3 sites are excluded (data not shown). In all lineage-
specific analyses, we started with the same initial set of human-based whole-genome alignments 
and human-based conserved noncoding elements, so as to maintain consistency in the input data. 
 
Gene Ontology analyses 
GO terms (http://www.godatabase.org/) of human RefSeq genes were augmented with those of 
their mouse and rat orthologs, as defined by Homologene  
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=homologene). CNSs were assigned the 
human-mouse-rat biological process and cellular component GO terms of the closest human 
RefSeq gene (3' or 5' end). It is possible that a different gene might be closer to the CNS in the 
chimpanzee or mouse genomes. However, in analyzing chimpanzee- and mouse-specific CNS 
acceleration, we retained the human-based CNS annotations for consistency.  Since 90% of the 
human and mouse genomes lie within syntenic blocks that are on average 6.9 Mb long, the 
human CNS-gene associations will in the majority of cases be preserved in mouse (8). By 
random chance 0.86% of human, 0.91% of chimpanzee and 4% of mouse CNSs associated with 
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a GO term are expected to be accelerated. Enrichment relative to this expectation was calculated 
using Fisher's exact test (one-tailed). Enriched parent GO terms of which all of the enrichment 
derives from a single daughter GO term were discarded. In order to ensure that the results 
reflected broad genomic trends rather locus-specific events, GO terms associated with < 10 
accelerated CNSs (an arbitrarily chosen cutoff) were eliminated to minimize artifacts of multiple 
testing. Human genes were annotated as “neuronal” by searching for the keywords “neuron*,” 
“neural*,” “neurite,” or “axon” on the Entrez Gene server 
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Gene). Entrez Gene records are gene-
specific, text-based annotations that are manually curated using data from the primary literature. 
 
In all, we tested 3,594 biological process GO terms and 672 cellular component GO terms for 
association with accelerated CNSs. Given the hierarchical structure of the ontologies, and the 
fact that each gene in general has multiple GO-term associations, it is difficult to analytically 
correct GO-term enrichment P-values for the effect of multiple testing. We therefore estimated 
the effect of multiple testing by randomly labeling 1,119 human, 1,180 chimpanzee and 5,058 
mouse CNSs as accelerated and testing each of the GO terms for enrichment in these CNSs. We 
performed 1,000 iterations of this randomization procedure, and estimated the P-value threshold 
at which only one GO term is expected to be significantly associated with accelerated CNSs by 
random chance. The resulting thresholds were P = 0.004 for human and chimpanzee biological 
process GO terms, P = 0.0051 for mouse biological process GO terms, P = 0.024 for human and 
chimpanzee cellular component GO terms, and P = 0.030 for mouse cellular component GO 
terms. 
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Correlation with recent positive selection in humans as revealed by polymorphism data 
We examined the overlap between our accelerated CNSs and regions of the human genome 
showing evidence of recent selection in a genome-wide analysis of polymorphism data (9) but 
we saw no significant correlation between the datasets (data not shown). This is likely because 
the vast majority of accelerated CNSs we observe accumulated sequence changes throughout the 
course of human evolution following the divergence of the human and chimpanzee lineages. We 
are measuring acceleration over the entire ~6 million year course of human evolution since the 
divergence of humans and chimpanzees. SNP-based analyses of adaptive evolution can only 
detect selective sweeps occurring in the last 200,000 years of human evolution (10). This is 
1/30th of the time scale we are actually considering in our analysis. 
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Supplemental Tables 
Table S1. (A) CNSs accelerated in the human lineage. N1, N2, N3: number of Type1, Type2 and 
Type3 positions in the CNS. K1, K2, K3: number of Type1, Type2 and Type3 substitutions in 
the CNS. Coordinates are based on the human May 2004 (hg17) genome assembly. (B) CNSs 
accelerated in the chimpanzee lineage (human coordinates). (C) CNSs accelerated in the mouse 
lineage (human coordinates). (D) Biological processes and cellular components significantly 
associated with CNSs accelerated in human. (E) Biological processes and cellular components 
significantly associated with CNSs accelerated in chimpanzee. (F) Biological processes and 
cellular components significantly associated with CNSs accelerated in mouse. (G) CNS and P-
value thresholds for process and component associations of accelerated CNSs (adjustment for 
multiple testing). 
 
